UCLA AIDS Institute and Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, 10833 Le Conte Ave., Los Angeles, CA 90095-1745, USA.
Immunol Res. 2010 Dec;48(1-3):59-71. doi: 10.1007/s12026-010-8167-9.
Older individuals (≥50 years of age) are increasingly becoming a new at-risk group for HIV-1 infection and, together with those surviving longer due to the introduction of anti-retroviral therapy (ART), it is predicted that more than half of all HIV-1-infected individuals in the United States will be greater than 50 years of age in the year 2015. Older individuals diagnosed with HIV-1 are prone to faster disease progression and reduced T-cell reconstitution despite successful virologic control with anti-retroviral therapy (ART). There is also growing evidence that the T-cell compartment in HIV-1(+) adults displays an aged phenotype, and HIV-1-infected individuals are increasingly diagnosed with clinical conditions more commonly seen in older uninfected persons. As aging in the absence of HIV infection is associated with alterations in T-cell function and immunosenescence, the combined impact of both HIV-1 infection and aging may provide an explanation for poorer clinical outcomes observed in older HIV-1-infected individuals. Thus, the development of novel therapeutics to stimulate immune function and delay immunosenescence is critical and would be beneficial to both the elderly and HIV-1-infected individuals.
老年人（≥50 岁）正逐渐成为 HIV-1 感染的新高危人群，而且随着抗逆转录病毒疗法（ART）的引入，预计到 2015 年，美国超过一半的 HIV-1 感染者年龄将超过 50 岁。尽管抗逆转录病毒疗法（ART）能够成功控制病毒，但诊断出 HIV-1 的老年人更容易出现疾病快速进展和 T 细胞重建减少的情况。越来越多的证据表明，HIV-1（+）成年人的 T 细胞群表现出衰老表型，而且 HIV-1 感染者越来越多地被诊断出患有更常见于未感染老年人的临床疾病。由于在没有 HIV 感染的情况下衰老与 T 细胞功能改变和免疫衰老有关，因此 HIV-1 感染和衰老的综合影响可能可以解释为什么老年 HIV-1 感染者的临床结局较差。因此，开发新型治疗方法来刺激免疫功能和延缓免疫衰老至关重要，这对老年人和 HIV-1 感染者都有益。
